New diabetes drugs changing treatment in the US
Type 2 diabetes medicines like Ozempic, marketed by Novo Nordisk, have doctors replacing the old with the new.
by marketwire, translated by daniel pedersen
Doctors in the US are changing with the times after new treatments for type 2 diabetes like SGLT-1 and GLP-1 drugs have taken the market by storm, writes The Wall Street Journal. Danish drugmaker Novo Nordisk’s best-selling diabetes medicine, Ozempic (semaglutide), is in the latter category.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Eli Lilly to lower insulin prices by 70% in US
For subscribers
Demand for Novo Nordisk's Wegovy accelerating
For subscribers
.jpg&w=384&q=75)
